CCO Management Series

Learning Objectives

Upon completion of this activity, participants should be able to:

• Identify the primary barriers to patient accrual in non-small-cell lung cancer clinical trials
• Recall current statistics regarding lung cancer in the United States
• Describe the current state of lung cancer clinical trial accrual and prioritization of increasing these numbers

Topics covered include:

• Introduction
• Adjuvant and Neoadjuvant Chemotherapy
• Targeted Therapies
• Priority Trials in Early-Stage NSCLC
• Treatment of Locally Advanced NSCLC

Learning Objectives

Upon completion of this activity, participants should be able to:

• Review the use of adjuvant and neoadjuvant therapy in the setting of NSCLC
• Discuss reasons for low enrollment in lung cancer clinical trials
• Summarize the use of epidermal growth factor receptor tyrosine kinase inhibitors in patients with NSCLC

Topics covered include:

• The Premise of Screening
• Experience From Early Chest Radiography Screening Trials
• Trials Evaluating CT Screening
• Molecular Screening Techniques
• Categories and Staging in NSCLC

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe key clinical trial data regarding computed tomography screening in the setting of NSCLC
• Discuss molecular screening tools in NSCLC
• Define staging classifications of NSCLC

Topics covered include:

• Epidemiology of Advanced NSCLC
• Current Standard Treatment for Patients With Advanced Disease
• Targeted Agents for the First-Line Treatment of NSCLC
• Optimizing Patient Selection
• Second-Line Treatment Options for Advanced NSCLC

Learning Objectives

Upon completion of this activity, participants should be able to:

• Review clinical trial results of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
• Describe future therapeutic approaches to NSCLC
• Summarize the use of bevacizumab and cetuximab in the treatment of advanced NSCLC

Topics covered include:

• Introduction
• Epidermal Growth Factor Receptor Inhibitors
• Antiangiogenic Agents
• Multikinase Inhibitors
• PI3K-Akt-mTOR Pathway

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe the use of epidermal growth factor inhibitors in the setting of NSCLC
• Discuss clinical data regarding the use of bevacizumab in NSCLC
• Summarize the use of kinase inhibitors in patients with lung cancer